Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy

• Status: RECRUITING
• Trial end date: 2029-06-01

Summary

This study is a Phase II, multi-site, randomized, open-label clinical study to evaluate the safety, efficacy, and pharmacokinetics (PK) of BNT327 at two dose levels in combination with chemotherapeutic agents in the first- and second-line treatment of participants with locally advanced/metastatic triple-negative breast cancer (mTNBC).

• Phase: PHASE2

Details

• Lead Sponsor: BioNTech SE
• Treatments: Carboplatin; eribulin; Gemcitabine; Paclitaxel